|
1
|
Debarros M and Steele SR: Colorectal
cancer screening in an equal access healthcare system. J Cancer.
4:270–280. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qaseem A, Denberg TD, Hopkins RH Jr,
Humphrey LL, Levine J, Sweet DE and Shekelle P: Clinical Guidelines
Committee of the American College of Physicians: Screening for
colorectal cancer: A guidance statement from the American College
of Physicians. Ann Intern Med. 156:378–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ragnhammar P, Hafström L, Nygren P and
Glimelius B: SBU-group. Swedish Council of Technology Assessment in
Health Care: A systematic overview of chemotherapy effects in
colorectal cancer. Acta Oncol. 40:282–308. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bergsland EK: Is more not better?
Combination therapies in colorectal cancer treatment. Hematol Oncol
Clin North Am. 29:85–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saltz LB and Minsky B: Adjuvant therapy of
cancers of the colon and rectum. Surg Clin North Am. 82:1035–1058.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bauer TW and Spitz FR: Adjuvant and
neoadjuvant chemoradiation therapy for primary colorectal cancer.
Surg Oncol. 7:175–181. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moss JA: Gene therapy review. Radiol
Technol. 86:155–184. 2014.PubMed/NCBI
|
|
9
|
Roth JA and Cristiano RJ: Gene therapy for
cancer: What have we done and where are we going? J Natl Cancer
Inst. 89:21–39. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalla R, Ventham NT, Kennedy NA, Quintana
JF, Nimmo ER, Buck AH and Satsangi J: MicroRNAs: New players in
IBD. Gut. 64:504–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xue J, Niu J, Wu J and Wu ZH: MicroRNAs in
cancer therapeutic response: Friend and foe. World J Clin Oncol.
5:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: MicroRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Menghini R, Casagrande V, Cardellini M,
Martelli E, Terrinoni A, Amati F, Vasa-Nicotera M, Ippoliti A,
Novelli G, Melino G, et al: MicroRNA 217 modulates endothelial cell
senescence via silent information regulator 1. Circulation.
120:1524–1532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kato M, Putta S, Wang M, Yuan H, Lanting
L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, et al:
TGF-beta activates Akt kinase through a microRNA-dependent
amplifying circuit targeting PTEN. Nat Cell Biol. 11:881–889. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Voong LN, Slater AR, Kratovac S and
Cressman DE: Mitogen-activated protein kinase ERK1/2 regulates the
class II transactivator. J Biol Chem. 283:9031–9039. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giehl K, Skripczynski B, Mansard A, Menke
A and Gierschik P: Growth factor-dependent activation of the
Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell
line PANC-1 carrying activated K-ras: Implications for cell
proliferation and cell migration. Oncogene. 19:2930–2942. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Y, Xiao T, Zhang F, Chen Y, Liu Y, Li
Y, Chen YD, Li Z and Guan M: Effect of mitochondrial tRNA(Lys)
mutation on the clinical and biochemical characteristics of Chinese
essential hypertensive subjects. Biochem Biophys Res Commun.
454:500–504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Qian J, Wang J, Luo C, Chen J, Hu
G and Lu Y: Knockdown of RLIP76 expression by RNA interference
inhibits invasion, induces cell cycle arrest, and increases
chemosensitivity to the anticancer drug temozolomide in glioma
cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hui AB, Shi W, Boutros PC, Miller N,
Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L,
Jurisica I, et al: Robust global micro-RNA profiling with
formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest.
89:597–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu
YC, Hu GH, Luo C and Chen JX: RLIP76 is overexpressed in human
glioblastomas and is required for proliferation, tumorigenesis and
suppression of apoptosis. Carcinogenesis. 34:916–926. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subramanian M and Shaha C: Upregulation of
Bcl-2 through ERK phosphorylation is associated with human
macrophage survival in an estrogen microenvironment. J Immunol.
179:2330–2338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vitagliano O, Addeo R, D'Angelo V, Indolfi
C, Indolfi P and Casale F: The Bcl-2/Bax and Ras/Raf/MEK/ERK
signaling pathways: Implications in pediatric leukemia pathogenesis
and new prospects for therapeutic approaches. Expert Rev Hematol.
6:587–597. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lemieux E, Cagnol S, Beaudry K, Carrier J
and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin
pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo J, Feng Z, Huang Z, Wang H and Lu W:
MicroRNA-217 functions as a tumor suppressor gene and correlates
with cell resistance to cisplatin in lung cancer. Mol Cells.
37:664–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Yébenes VG, Bartolomé-Izquierdo N,
Nogales-Cadenas R, Pérez-Durán P, Mur SM, Martínez N, Di Lisio L,
Robbiani DF, Pascual-Montano A, Cañamero M, et al: MiR-217 is an
oncogene that enhances the germinal center reaction. Blood.
124:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Joshi S and Platanias LC: Mnk kinase
pathway: Cellular functions and biological outcomes. World J Biol
Chem. 5:321–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bates DJ and Lewis LD: Manipulating the
apoptotic pathway: Potential therapeutics for cancer patients. Br J
Clin Pharmacol. 76:381–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang T and Saghatelian A: Emerging roles
of lipids in BCL-2 family-regulated apoptosis. Biochim Biophys
Acta. 1831:1542–1554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ye L, Yuan G, Xu F, Sun Y, Chen Z, Chen M,
Li T, Sun P, Li S and Sun J: The small-molecule compound BM-1197
inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers
apoptotic cell death in human colorectal cancer cells. Tumour Biol.
36:3447–3455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao SL, Hong J, Xie ZQ, Tang JT, Su WY,
Du W, Chen YX, Lu R, Sun DF and Fang JY: TRAPPC4-ERK2 interaction
activates ERK1/2, modulates its nuclear localization and regulates
proliferation and apoptosis of colorectal cancer cells. PLoS One.
6:e232622011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abdel-Magid AF: ERK2 inhibitors may
provide treatment for cancer. ACS Med Chem Lett. 4:576–577. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang D, Weng Q, Zhang L, He Q and Yang B:
VEGF and Bcl-2 interact via MAPKs signaling pathway in the response
to hypoxia in neuroblastoma. Cell Mol Neurobiol. 29:391–401. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scheid MP, Schubert KM and Duronio V:
Regulation of bad phosphorylation and association with Bcl-x(L) by
the MAPK/Erk kinase. J Biol Chem. 274:31108–31113. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Orton RJ, Sturm OE, Vyshemirsky V, Calder
M, Gilbert DR and Kolch W: Computational modelling of the
receptor-tyrosine-kinase-activated MAPK pathway. Biochem J.
392:249–261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng Y, Zhang G and Li G: Targeting MAPK
pathway in melanoma therapy. Cancer Metastasis Rev. 32:567–584.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Furukawa K and Hohmann S: Synthetic
biology: Lessons from engineering yeast MAPK signalling pathways.
Mol Microbiol. 88:5–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pritchard AL and Hayward NK: Molecular
pathways: Mitogen-activated protein kinase pathway mutations and
drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zassadowski F, Rochette-Egly C, Chomienne
C and Cassinat B: Regulation of the transcriptional activity of
nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal.
24:2369–2377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Collins MA and di Magliano M Pasca: Kras
as a key oncogene and therapeutic target in pancreatic cancer.
Front Physiol. 4:4072013.PubMed/NCBI
|
|
44
|
Sundaram MV: RTK/Ras/MAPK signaling.
WormBook. 1–19. 2006.PubMed/NCBI
|
